n/a (IDNA)

Moderna’s vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.

Biotech ETFs are surging in 2026 as a friendlier FDA, strong M&A activity and AI-driven drug discovery fuel optimism for more upside.

Genomics companies are an exciting frontier in health care, and ETFs can help to diversify to control risk while positioning investors to benefit.

AI fears rattled markets as IBM sank and tech slid, but ETFs like OIH, BWET, IDNA and HDGE stayed resilient, gaining even as major indexes fell.

Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.